• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/1/25 4:08:18 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email
    bmrn-20250501
    0001048477false00010484772025-05-012025-05-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 1, 2025

    BioMarin Pharmaceutical Inc.
    (Exact name of registrant as specified in its charter)
    Delaware
    000-26727
    68-0397820
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    770 Lindaro Street
    San Rafael
    California
    94901
    (Address of Principal Executive Offices)
    (Zip Code)
    (415) 506-6700
    (Registrant's telephone number, including area code)

    Not Applicable
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.001BMRNThe Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    o



    Item 2.02 Results of Operations and Financial Condition.

    On May 1, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2025. The Company’s press release issued on May 1, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

    The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.



    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.
    Exhibit NumberDescription
    99.1
    Press Release of the Company dated May 1, 2025
    104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    BioMarin Pharmaceutical Inc.,
    a Delaware corporation
    Date: May 1, 2025
    By:/s/ G. Eric Davis
    G. Eric Davis
    Executive Vice President, Chief Legal Officer


    Get the next $BMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    5/17/2024$104.00 → $72.00Outperform → Neutral
    Robert W. Baird
    5/14/2024$113.00Outperform
    Evercore ISI
    11/15/2023$100.00Overweight
    Wells Fargo
    More analyst ratings

    $BMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

      For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

      6/29/23 6:02:12 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    SEC Filings

    See more
    • SEC Form 8-K filed by BioMarin Pharmaceutical Inc.

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/22/25 4:05:34 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by BioMarin Pharmaceutical Inc.

      SC TO-C - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      5/16/25 7:59:36 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/16/25 7:54:33 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Hubbard Cristin covered exercise/tax liability with 2,155 shares, decreasing direct ownership by 7% to 30,545 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:02:57 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walbert Timothy P was granted 6,650 shares, increasing direct ownership by 212% to 9,780 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:01:26 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Meier Richard A was granted 6,650 shares, increasing direct ownership by 6% to 127,426 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:00:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

      Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025. The Phase 3 GENEr8-1

      6/24/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioMarin Pharmaceutical upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BioMarin Pharmaceutical from Perform to Outperform and set a new price target of $98.00

      2/24/25 8:15:22 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on BioMarin Pharmaceutical with a new price target

      Wolfe Research initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $95.00

      11/15/24 7:39:24 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical downgraded by William Blair

      William Blair downgraded BioMarin Pharmaceutical from Outperform to Mkt Perform

      10/30/24 6:37:15 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

      SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025. Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition by Amgen in 2023. Mr. Walbert is currently senior advisor, Amgen. Prior to Horizon, Mr. Walbert served as president and chief executive officer of IDM Pharma, w

      2/24/25 4:05:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Financials

    Live finance-specific insights

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

      First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y)  Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., May 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2025. "During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth

      5/1/25 4:05:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioMarin Pharmaceutical Inc.

      SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      9/30/24 4:29:01 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

      SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      7/10/24 1:14:41 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

      SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      7/8/24 4:32:41 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care